PRESS-RELEASE ·Filed Oct 29, 2026
Press release · FDA
Actionable Insight • Neutral
Monitor Phase 2 enrollment updates and initial data readout in Q4 2027. Gilead's decision on the option after Phase 2 completion is the next major catalyst.
Price Chart
Loading chart...
Executive Summary
Assembly Biosciences announced dosing of the first two participants in a Phase 2 study of ABI-6250, an oral entry inhibitor for chronic HDV infection. Initial data is expected in Q4 2027. Gilead has an option to license ABI-6250 after the Phase 2 study for a $90 million opt-in fee.
Key Financial Metrics
Deal Value
$90.0M
Key Facts
- First two participants dosed in Phase 2 study (ABI-6250-201) of ABI-6250 for chronic HDV infection.
- Phase 2 study expected to enroll ~80 participants; initial data expected Q4 2027.
- Gilead has option to obtain exclusive license for ABI-6250 after Phase 2 completion for a $90 million opt-in fee.
- ABI-6250 is an oral small-molecule NTCP inhibitor; only approved HDV therapy requires daily injections.
- Phase 1a data showed safety and PK profile supporting once-daily oral dosing with ~4-day half-life.
Financial Impact
Gilead opt-in fee of $90 million is potential near-term milestone; no revenue yet.
revenuemilestone payments
Risk Factors
- Phase 2 study may fail to show sufficient antiviral activity or safety.
- Gilead may decline to exercise its option, eliminating a key partnership value.
- Competition from existing injectable HDV therapy and other pipeline candidates.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3391795 |
11 reports for ASMB
75% Hit rate @ T+5 Went positive at some point 4 of 4 best @ T+20▲ +9.08%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | Press Release | $20.86 | awaiting T+5 | awaiting T+5 | $20.13 (−3.50%) |
Aug 15, 2026 11w ago | Institutional Cluster | $30.01 $35.28 | ▲ +17.56% | ▲ +18.75% | $20.13 (−32.92%) |
Aug 13, 2026 11w ago | Press Release | $32.95 $34.38 | ▲ +4.34% | ▲ +5.71% | $20.13 (−38.91%) |
Jun 11, 2026 20w ago | Institutional Cluster | $22.53 $24.15 | ▲ +7.19% | ▲ +6.76% | $20.13 (−10.65%) |
Jun 5, 2026 21w ago | 8-K | $22.56 $23.34 | ▲ +3.48% | ▲ +1.37% | $20.13 (−10.75%) |
May 22, 2026 23w ago | 424B5 | $28.75 $26.92 | ▲ +6.37% | ▲ +7.45% | $20.13 (+29.98%) |
May 22, 2026 23w ago | 8-K | $28.34 $26.92 | ▼ −5.01% | ▼ −6.67% | $20.13 (−28.97%) |
May 22, 2026 23w ago | Press Release | $28.34 $26.92 | ▼ −5.01% | ▼ −6.67% | $20.13 (−28.97%) |
May 7, 2026 25w ago | Press Release | $29.74 $30.30 | ▲ +1.88% | ▲ +0.42% | $20.13 (−32.31%) |
Mar 30, 2026 30w ago | EFFECT | $26.64 $28.53 | ▲ +7.09% | ▲ +2.79% | $20.13 (−24.44%) |
Showing 10 of 11
US Market Status
Market Closed · Opens Mon (< 1m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers